Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6189687 | 0.99 | CCR5 (0.45) | CCR5CYP3A4CYP2C9CXCR4CYP2D6 | |
| SCHEMBL5612301 | 0.89 | CCR5 (0.48) | CCR5CYP3A4CYP2C9CXCR4CYP2D6 | |
| SCHEMBL4828471 | 0.82 | CCR5 (0.44) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5346530 | 0.82 | CCR5 (0.40) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5340685 | 0.82 | CCR5 (0.40) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5612320 | 0.82 | CCR5 (0.61) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14381400 | 0.82 | CCR5 (0.61) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6012736 | 0.82 | CCR5 (0.61) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186871 | 0.81 | CCR5 (0.56) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5344130 | 0.81 | CCR5 (0.62) | CCR5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361758-B2 | Crystals of triazaspiro[5.5]undecane derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ONO PHARMACEUTICAL CO,., LTD (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1541573-A1 | NOVEL CRYSTALS OF TRIAZASPIRO 5.5 UNDECANE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ACKR3, CCR10, CCR9 | CCR5 4/4885CYP3A4 1510/4885CYP2C9 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.